Navigation Links
5 Washington organizations make joint grant
Date:9/7/2013

SEATTLE, Washington, September 5, 2013 A product development team at the University of Washington (UW) will receive $390,000 from five organizations dedicated to fostering technology commercialization in Washington.

The grant will support refinement and clinical testing of a handheld device to improve treatment of trauma, which is the leading cause of death for people under age 45. Trauma patients often die from excessive bleeding; blood loss can be worsened by a hard-to-diagnose condition called trauma-induced coagulopathy (TIC). A team led by Nathan Sniadecki in the UW Department of Mechanical Engineering and Nathan White in the UW Department of Medicine, Division of Emergency Medicine, is developing a tool to rapidly detect TIC and thus permit immediate and appropriate treatment of this life-threatening condition. The device will measure the ability of the blood to clot during trauma, which can take up to half an hour to detect with current technology. The team has also formed a company, Stasys, to license the technology and bring the product to market.

This grant is funded by the Coulter Translational Research Partnership Program at UW, the Life Sciences Discovery Fund (LSDF), the Institute of Translational Health Sciences, the UW Center for Commercialization (C4C), and the Washington Research Foundation.

"Each of our organizations actively funds research and development in Washington to help move promising technologies from the academic into the commercial environment," explained Patrick Shelby, director of New Ventures at C4C.

"There has been substantial overlap in the projects that we support, with several projects receiving funding from all five programs serially for different work plans. This grant is based on our belief that joint funding for a single work plan will drive faster and more efficient commercial development than serial funding."

The TIC detection device project was reviewed by external experts for scientific and technical merit, commercial potential, and possible health and economic benefits.

Shelby expressed his desire that based on the success of this initial award, the funding organizations would consider collaborating in funding future grants. John DesRosier, executive director of LSDF, further noted that this was the first time LSDF had partnered with other granting entities and stated that he hoped that this model could be replicated with other Washington universities and institutions.


'/>"/>

Contact: Cathyryne Manner
manner@lsdfa.org
206-456-9583
Life Sciences Discovery Fund
Source:Eurekalert

Related biology technology :

1. SoundConnect Announces Expansion into New York City and Washington D.C.
2. BioLife Solutions Named One of Washingtons Best Companies
3. Douglas Harrington, MD Speaks At American Academy Of Physicians Assistants 2013 Conference In Washington, DC
4. Washington State University to Present on Tin Nanoneedles: A Technology for Lithium-ion Batteries, at Knowledge Foundation’s Next Generation Batteries 2013 Conference
5. New Strain of Bacteria May Clear up Acne Probiotic Action Explains the New Research Findings from Washington University
6. Bed Bugs Find Their Way to University of Washington and Hastings-on-Hudson Libraries; Bed Bug Control 911 Advises Use of Bed Bug Spray to Effectively Clear the Pests Away
7. EcoSolutions Prevents Flooding in Washington D.C.
8. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
9. National Defense Industrial Association (NDIA) Opens Registration For 2012 Biosurveillance Conference, Set For August 27-28 in Washington, D.C.
10. CMC Biologics Honored as Finalist for Washingtons Manufacturing Company of the Year Award
11. Core and More Technologies Helps Organizations Migrate to Google’s Enhanced Campaign Structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... innovation and business process optimization firm for the life sciences and healthcare industries, ... conference in San Francisco. , The presentation, “Automating GxP Validation for Agile ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):